Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population

Who May Qualify: - Must meet criteria of the high-risk population as described with one of the below criteria - ≥ 30 years AND - first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer. OR - Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer ' - Voluntary written willing to sign a consent form must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care Who Should NOT Join This Trial: - • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy. - Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia - Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test. Always talk to your doctor about whether this trial is right for you.